Gilead’s New Perspectives on HIV

In this ISSUE

Why Pharma Should Pay Attention to Copay Accumulator Programs

5 Ways to Shape a Regulatory Affairs Workforce for the Future

3 Key Dynamics to Understand for Canadian Market Access

Top Story

Gilead's New Perspectives on HIV

Hilary Hutton-Squire, Gilead's UK & Ireland General Manager, talks to Pharm Exec about the company's new "HIV Age Positively" campaign
… /Read more/

Pharmaceutical Executive: Emerging Pharma Leaders
Meet these winners who are vital to the future of the industry

Read the article

Regulatory

FDA Maps Strategy to Broaden Use of Real-World Evidence

To further streamline product development and facilitate post market safety surveillance, the agency has developed a new Framework for Real-World Evidence that spells out opportunities and concerns in advancing these approaches. Jill Wechsler reports /Read more/

Regulatory

EU Must Address Polarization of Health Policy Debate

As the EU prepares for a change of governance, policymakers should take note of recent comments about the "poisoned atmosphere" surrounding healthcare policy debates, writes Reflector
… /Read more/

Calendar

/ January 22–23, 2019: 14^th Biosimilars Summit /

Alexandria, VA

/ January 23–24, 2019: Data Analytics and Decisions /

Philadelphia, PA

/ January 24–25, 2019: Specialty Therapies 2019 /

Las Vegas, NV

/ January 29–30, 2019: 6^th Annual Clinical Data Disclosure and Transparency /

Philadelphia, PA

/ February 4–5, 2019: Disease Awareness Campaigns /

Philadelphia, PA

/ March 4–6, 2019: 20th Annual Patient Assistance and Access Programs – PAP 2019 /

Baltimore, MD

/ March 12–13, 2019: Pharmaceutical Compliance Congress Asia /

Shanghai, China

Business Models

The Biopharma-Led Platform Business Model in Healthcare

The potential for resulting disruption of incumbent business models is real. Ruchin Kansal looks at what we can learn from an early leader
… /Read More/

Audio

The Pharm Exec Podcast: Virtual Reality and Marketing

Nicola Kayel, Vice President of Marketing at Salix Pharmaceuticals, speaks to the Pharm Exec editors about the company's recent plunge into virtual and augmented reality
… /Read More/

Industry update

// Melinta Therapeutics (New Haven, CT) announced that John H. Johnson has agreed to become the permanent CEO, subject to contract and the close of the commitment for a credit facility of up to $135 million from Vatera Healthcare Partners, LLC. Mr. Johnson is a director of Melinta and has served as interim CEO of the Company since October 22, 2018. // CytoDyn (Vancouver, WA) hired Nitya G. Ray, Ph.D. to serve as its new Chief Technology Officer – Head of Process Sciences, Manufacturing & Supply Chain. // resTORbio (Boston, MA) appointed William Marshall, M.D., as Vice President of Medical Sciences. // Nkarta Therapeutics (South San Francisco, CA) appointed Matthew Plunkett, Ph.D., as Senior Vice President and Chief Financial Officer. // miRagen Therapeutics (Boulder, CO) announced the appointment of Jeff Hatfield, a Director since 2017, as Chairman of the Board of Directors. // Imprimis Pharmaceuticals (San Diego, CA) announced the completion of its name change to Harrow Health, Inc.

advertise with us / print subscribe / digital subscribe / visit pharmexec.com